Start
Features
Free trial / FAQ

Researchers
Physicians
Pharmacists
Ecotrophologists
Product Managers
in Health Industries

Loading…

Medical Research Finder

Legal Notice
Privacy
Terms of Use

meRfi® Microbiome - The Digital Gut Microbiome Reference (incl. AI Chat)
Prebiotics, Probiotics, FMT / Manipulators of the Intestinal Microbiota

AuthorsReferences (Sources)

meRfi® AI Chat

Melanoma (cutaneous) (KIT m)

Welcome to meRfi Microbiome!

Please register to continue your trial period!

meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.

Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.

Start your free trial and transform your understanding of the gut microbiota today!

(Login)

Navigation

Imatinib or Nilotinib can be effective in Melanoma (cutaneous) (KIT m)
Awada & Neyns 2022 Current Opinion in Oncology 34(2): 115-122

KIT mutations occur infrequently in Melanoma (cutaneous), but this frequency increase to 22% when we focus on the subgroup of triple wild type melanoma (wild type for BRAF, NRAS and NF1)
Delyon et al. 2020 Current Opinion in Oncology. 32(2): 79-84

11% of Melanoma (cutaneous) cases are KIT mutated
Minor et al., 2012

KIT mutations may represent an adverse prognostic factor in metastatic melanoma
Minor et al., 2012

…

References (Sources)

Melanoma with genetic alterations beyond the BRAF V600 management and new insights
Awada & Neyns 2022 Current Opinion in Oncology 34(2): 115-122
Review
Sunitinib Therapy for Melanoma Patients with KIT Mutations
Minor et al., 2012
Targeted therapies in melanoma beyond BRAF targeting NRAS mutated and KIT mutated melanoma
Delyon et al. 2020 Current Opinion in Oncology. 32(2): 79-84

AI Chat

7/1/2026

Chat with our artificial intelligence:

Start chat!

Melanoma (cutaneous) (KIT m)

Welcome to meRfi Microbiome!

Navigation

Contents

References (Sources)

AI Chat